Metal nanoparticles for cancer therapy: Precision targeting of DNA damage

Chen, Qian; Fang, Chunyan; Xia, Fan; Wang, Qiyue; Li, Fangyuan; Ling, Daishun

doi:10.1016/j.apsb.2023.08.031

Cited by 3 publications

(2 citation statements)

References 150 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Gold nanoparticles (AuNPs) have various biological applications 2–4 owing to their unique surface chemical, 5 electrical, 6 and optical properties. 7 Contrast agents based on gold nanoparticles 8 have been developed for various applications, including computed tomography (CT), 9 magnetic resonance imaging (MRI), 10 single-photon emission computed tomography (SPECT), 11 fluorescence imaging, 12 and others, with the aim of amplifying the sensitivity and precision of these imaging modalities.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Radiolabeled multi-layered coated gold nanoparticles as potential biocompatible PET/SPECT tracers

Uritu,

Al-Matarneh,

Bostiog

et al. 2024

J. Mater. Chem. B

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

“…Gold nanoparticles (AuNPs) have various biological applications [2][3][4] owing to their unique surface chemical, 5…”

Section: Introductionmentioning

confidence: 99%

Radiolabeled multi-layered coated gold nanoparticles as potential biocompatible PET/SPECT tracers

Uritu,

Al-Matarneh,

Bostiog

et al. 2024

J. Mater. Chem. B

View full text Add to dashboard Cite

show abstract

Next-generation aluminum adjuvants: Immunomodulatory layered double hydroxide NanoAlum reengineered from first-line drugs

Su,

Boucetta,

Shao

et al. 2024

Acta Pharmaceutica Sinica B

View full text Add to dashboard Cite

Donafenib inhibits PARP1 expression and induces DNA damage, in combination with PARP1 inhibitors promotes apoptosis in liver cancer cells

Jiang,

Yang,

et al. 2024

Anti-Cancer Drugs

View full text Add to dashboard Cite

Liver cancer is a prevalent malignant tumor globally. The newly approved first-line drug, donafenib, is a novel oral small molecule multi-tyrosine kinase inhibitor that has significant antitumor effects on liver cancer. This study aims to investigate the antitumor effects of donafenib on liver cancer and to explore its potential mechanisms. Donafenib significantly inhibited the viability of Huh-7 and HCCLM3 cells, inhibited malignant cell proliferation, and promoted cell apoptosis, as demonstrated by CCK-8, EdU, and Calcein/PI (propidium iodide) staining experiments. The results of DNA damage detection experiments and western blot analysis indicate that donafenib caused considerable DNA damage in liver cancer cells. The analysis of poly (ADP-ribose) polymerase 1 (PARP1) in liver cancer patients using online bioinformatics data websites such as TIMER2.0, GEPIA, UALCAN, cBioPortal, Kaplan–Meier Plotter, and HPA revealed a high expression of PARP1, which is associated with poor prognosis. Molecular docking and western blot analysis demonstrated that donafenib can directly target and downregulate the protein expression of PARP1, a DNA damage repair protein, thereby promoting DNA damage in liver cancer cells. Western blot and immunofluorescence detection showed that the group treated with donafenib combined with PARP1 inhibitor had significantly higher expression of γ-H2AX and 8-OHdG compared to the groups treated with donafenib or PARP1 inhibitors alone, the combined treatment suppresses the expression of the antiapoptotic protein Bcl2 and enhances the protein expression level of the proapoptotic protein Bcl-2-associated X protein (BAX). These data suggest that the combination of donafenib and a PARP1 inhibitor results in more significant DNA damage in cells and promotes cell apoptosis. Thus, the combination of donafenib and PARP1 inhibitors has the potential to be a treatment option for liver cancer.

show abstract

Metal nanoparticles for cancer therapy: Precision targeting of DNA damage

Cited by 3 publications

References 150 publications

Radiolabeled multi-layered coated gold nanoparticles as potential biocompatible PET/SPECT tracers

Radiolabeled multi-layered coated gold nanoparticles as potential biocompatible PET/SPECT tracers

Next-generation aluminum adjuvants: Immunomodulatory layered double hydroxide NanoAlum reengineered from first-line drugs

Donafenib inhibits PARP1 expression and induces DNA damage, in combination with PARP1 inhibitors promotes apoptosis in liver cancer cells

Contact Info

Product

Resources

About